Becton, Dickinson and Company (BD), founded in 1897 and headquartered in Franklin Lakes, New Jersey, USA, is a global medical technology company that develops, manufactures, and sells medical devices, instrument systems, and reagents. BD's extensive product portfolio includes syringes, needles, infusion therapy products, diagnostic instruments, and biosciences research tools, serving healthcare institutions, life science researchers, clinical laboratories, and the pharmaceutical industry. Committed to advancing the world of health, BD focuses on improving medical discovery, diagnostics, and the delivery of care. The company operates in more than 50 countries, employing approximately 70,000 associates worldwide.
BD launches the FACSDiscover™ A8 Cell Analyzer, combining spectral and real-time imaging for deeper, faster cellular insights in translational and biomarker research.
HemoSphere Alta Advanced Monitoring Platform with Predictive, Smart Algorithms Helps Clinicians Proactively Address Instability in Blood Flow and Pressure in Critical Situations.
The partnership aims to integrate BD flow cytometer software with Biosero's Green Button Go, supporting biopharma and CROs with robotic arm-compatible custom research solutions.
Focusing on biologics and self-care trends, BD advances drug delivery innovations to simplify treatment, enhance therapeutic outcomes, and support home-based healthcare solutions.
This innovative blood testing process integrates BD's MiniDraw Capillary Blood Collection System with Babson's BetterWay technologies to enable test results from as few as six drops of capillary blood collected from a patient's finger.
The companies have pre-assessed and streamlined integration of the BD Neopak XtraFlow Glass Prefillable Syringe with Ypsomed’s YpsoMate 2.25 autoinjector platform, to address limitations.